The GAPP promotes the commercialization and translation of genomics-derived technologies. It provides a unique opportunity for User organizations to leverage their R&D investments with public funding. GAPP fosters academic collaborations with Users from industry, government, not-for-profits, and other organizations. Successful projects are driven by the User and focus on areas of opportunity that they have identified.

Ontario Genomics is pleased to introduce this report on synthetic biology in Ontario.
Biology holds the key to all of humanity’s industrial, environmental and health challenges. What is left for us to do is pinpoint the right solutions from the genomes of millions of living organisms and put them to use in our factories, our hospitals and our homes.

Are you a Canadian IT, life sciences, robotics or foodtech company ready to grow and commercialize in the US market?

The Canadian Technology Accelerator in Boston is an award-winning 4-month immersion program that connects Canadian companies to US clients, strategic partners, and investors! Managed and operated by the Consulate General of Canada in Boston's Trade Commissioner Service team in close partnership with the CENE.

The Canadian Technology Accelerator (CTA) program of Global Affairs Canada provides Canadian high-growth companies with mentoring support, networking opportunities and temporary office space for greater exposure to global partners and markets. 

October 3, 2016 – Montreal, QC, Toronto and Ottawa, ON ─ KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co-developing since 2015.

The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom-engineered therapeutic developed at NRC.

September 20, 2016, New York — Synaptive Medical, a medical device company relentlessly pursuing connections to transform the process of care, has successfully installed their BrightMatter™ technology at Mount Sinai Health System in New York City. Mount Sinai, ranked #12 in the country by U.S. News & World Report for its neurology and neurosurgery program, is the first hospital in the New York Metropolitan area to acquire this revolutionary technology.

For the full press release, click here

Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. 

For the full press release, click here

For the Journal Article, click here

Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada. 

Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  

For the full press release, click here

September 09, 2016 - Toronto: To celebrate International PBC Day on September 11, 2016, Self Care Catalysts -- a patient intelligence and solutions company -- is announcing its newest self-care mobile app, created to support patients diagnosed with Primary Biliary Cholangitis (PBC). The team at Self Care Catalysts worked closely with the Canadian PBC Society to create a customized suite of self-care tools to support the total care for PBC, and to empower patients to play an active role in tracking their health story -- so that more can be understood about this rare disease.

For the full press release, click here